Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Evommune (EVMN) Cash & Equivalents (2024 - 2025)

Evommune (EVMN) has disclosed Cash & Equivalents for 2 consecutive years, with $44.1 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents rose 171.07% to $44.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $44.1 million through Dec 2025, up 171.07% year-over-year, with the annual reading at $44.1 million for FY2025, 171.07% up from the prior year.
  • Cash & Equivalents for Q4 2025 was $44.1 million at Evommune, up from $26.8 million in the prior quarter.
  • The five-year high for Cash & Equivalents was $44.1 million in Q4 2025, with the low at $16.3 million in Q4 2024.